Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Looks like house 009 wants us sub .20 a little longer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(30)
•••
Comment by 4real4everon Jan 30, 2021 4:37pm
268 Views
Post# 32429317

RE:RE:Looks like house 009 wants us sub .20 a little longer

RE:RE:Looks like house 009 wants us sub .20 a little longer

LithLover wrote:
I noticed that too. I was a buyer today. We will chew thru the low 20s in no time. 700,000 shares was double the average. Good accumulation. One thing I love about this company is the low float in strong hands. When it moves on an announcement of a partnership agreement we will see it move quickly.

 

Lithlover just a little reminder for you and your friends of what did you say in September 2016. We are in February 2021 if i remember correctly?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities